Evidence map›Paper›PMID 36186451›Full record

ArticleFrontiers in genetics2022

Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, China.

Weiguang Fan, Xiaodong Wang, Yuchen Zhang, Juan Meng, Miaomiao Su, Xuegang Yang, Haoxi Shi, Penghui Shi, Xinli Lu

Abstract read
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weiguang FanClinical Laboratory, The People's Hospital of Baoding, Baoding, Hebei, China.
Xiaodong WangInfection Division, The People's Hospital of Baoding, Baoding, Hebei, China.
Yuchen ZhangInfection Division, The People's Hospital of Baoding, Baoding, Hebei, China.
Juan MengInfection Division, The People's Hospital of Baoding, Baoding, Hebei, China.
Miaomiao SuInfection Division, The People's Hospital of Baoding, Baoding, Hebei, China.
Xuegang YangInfection Division, The People's Hospital of Baoding, Baoding, Hebei, China.
Haoxi ShiClinical Laboratory, The People's Hospital of Baoding, Baoding, Hebei, China.
Penghui ShiClinical Laboratory, The People's Hospital of Baoding, Baoding, Hebei, China.
Xinli LuDepartment of AIDS Research, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiretroviral therapy (ART) regimens containing integrase strand transfer inhibitors (INSTIs) are the recommended treatment for human immunodeficiency virus type 1 (HIV-1)-infected patients in the most recent guidelines in China. In this study, we investigated INSTI resistance mutations in newly diagnosed therapy-naive HIV-positive patients in Baoding City, Hebei Province (China) to provide guidance for implementing routine INSTI-associated HIV-1 genotypic resistance testing. Plasma samples were collected from HIV-1-infected patients without treatment at Baoding People's Hospital from January 2020 to December 2021. The part of HIV-1

Indexed as

baoding citydrug resistance mutationsgenotypeHIVintegrase strand transfer inhibitors

Identifiers

PMID36186451
PMCPMC9515489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.